GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EV Biologics Inc (OTCPK:YECO) » Definitions » Other Current Assets

EV Biologics (EV Biologics) Other Current Assets : $38.49 Mil (As of Dec. 2017)


View and export this data going back to 2015. Start your Free Trial

What is EV Biologics Other Current Assets?

EV Biologics's other current assets for the quarter that ended in Dec. 2017 was $38.49 Mil.

EV Biologics's quarterly other current assets declined from Dec. 2016 ($1.95 Mil) to Jun. 2017 ($1.91 Mil) but then increased from Jun. 2017 ($1.91 Mil) to Dec. 2017 ($38.49Mil).

EV Biologics's annual other current assets increased from Jun. 2015 ($0.68 Mil) to Jun. 2016 ($1.82 Mil) increased from Jun. 2016 ($1.82 Mil) to Jun. 2017 ($1.91 Mil).


EV Biologics Other Current Assets Historical Data

The historical data trend for EV Biologics's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EV Biologics Other Current Assets Chart

EV Biologics Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17
Other Current Assets
0.67 0.48 0.68 1.82 1.91

EV Biologics Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17 Dec17
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.82 1.96 1.95 1.91 38.49

EV Biologics Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


EV Biologics Other Current Assets Related Terms

Thank you for viewing the detailed overview of EV Biologics's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


EV Biologics (EV Biologics) Business Description

Traded in Other Exchanges
N/A
Address
1621 Central Avenue, Cheyenne, WY, USA, 82001
EV Biologics Inc is developing the extraordinary biological properties of extracellular vesicles (EVs) to create the next generation of diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions, increase natural longevity and transform lives.
Executives
Daniel S Mckinney director, 10 percent owner, officer: CEO TWO IFC, 19TH FLOOR, 8 FINANCE STREET, CENTRAL, HONG KONG F4 000000
Michael W Harlan director C/O WASTE CONNECTIONS, INC., 610 APPLEWOOD CRESCENT, SUITE 200, VAUGHAN A6 L4K 0C3

EV Biologics (EV Biologics) Headlines

From GuruFocus

EV Biologics Initiates PCAOB Audit to Seek Uplift to OTCQX

By ACCESSWIRE ACCESSWIRE 11-14-2022

EV Biologics Updates on Funding and Sales

By ACCESSWIRE 10-02-2023

EV Biologics NFT Dividend Update

By ACCESSWIRE ACCESSWIRE 07-19-2021

EV Biologics NFT Dividend Warrant Date

By ACCESSWIRE ACCESSWIRE 07-30-2021

EV Biologics Launches Excyte with $100 million Valuation

By ACCESSWIRE ACCESSWIRE 08-15-2022

EV Biologics Signs MSA with LONZA Cell & Gene Therapy

By ACCESSWIRE ACCESSWIRE 05-17-2022

EV Biologics Announces NFT Dividend

By ACCESSWIRE ACCESSWIRE 07-14-2021

EV Biologics Updates on Excyte Subsidiary Funding

By ACCESSWIRE ACCESSWIRE 01-03-2023